Drug intelligence / Profile preview

FibroStem

Development stage: Preclinical
Lead developer: Escape Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

FibroStem is a preclinical-stage allogeneic fibroblast cell therapy being developed by Escape Therapeutics, a California-based biotechnology company. The therapy utilizes 'universal' fibroblasts, which are designed to be immune-tolerant, allowing for off-the-shelf administration without the need for patient-specific HLA matching. FibroStem is intended to treat skin atrophy and scarring by restoring the population of functional dermal fibroblasts, which are responsible for the synthesis of collagen and other extracellular matrix components essential for skin integrity and repair. It is part of a broader pipeline of stem cell-based therapeutics focused on regenerative medicine and wound care.

Brand names: FibroStem
Other names: Universal fibroblasts

Beyond the preview

Go deeper on FibroStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FibroStem.

Explore the full profile